|Abiraterone and increased survival in metastatic prostate cancer|
JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ...
New England Journal of Medicine 364 (21), 1995-2005, 2011
|Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm …|
JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ...
The Lancet 387 (10031), 1909-1920, 2016
|Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors|
B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ...
Science 359 (6371), 91-97, 2018
|Enzalutamide in metastatic prostate cancer before chemotherapy|
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
|TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells|
S Mariathasan, SJ Turley, D Nickles, A Castiglioni, K Yuen, Y Wang, ...
Nature 554 (7693), 544-548, 2018
|MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer|
T Powles, JP Eder, GD Fine, FS Braiteh, Y Loriot, C Cruz, J Bellmunt, ...
Nature 515 (7528), 558-562, 2014
|Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial|
AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ...
The Lancet 389 (10064), 67-76, 2017
|Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 …|
T Powles, I Durán, MS Van der Heijden, Y Loriot, NJ Vogelzang, ...
The Lancet 391 (10122), 748-757, 2018
|Erdafitinib in locally advanced or metastatic urothelial carcinoma|
Y Loriot, A Necchi, SH Park, J Garcia-Donas, R Huddart, E Burgess, ...
New England Journal of Medicine 381 (4), 338-348, 2019
|High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 TrialGenomics to Improve Cancer Outcome|
C Massard, S Michiels, C Ferté, MC Le Deley, L Lacroix, A Hollebecque, ...
Cancer discovery 7 (6), 586-595, 2017
|Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma|
T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ...
New England Journal of Medicine 383 (13), 1218-1230, 2020
|Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)|
Y Loriot, D Bianchini, E Ileana, S Sandhu, A Patrikidou, C Pezaro, ...
Annals of oncology 24 (7), 1807-1812, 2013
|Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study|
TM Beer, AJ Armstrong, D Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
European urology 71 (2), 151-154, 2017
|Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial|
J Rodon, JC Soria, R Berger, WH Miller, E Rubin, A Kugel, A Tsimberidou, ...
Nature medicine 25 (5), 751-758, 2019
|EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients|
D Planchard, Y Loriot, F Andre, A Gobert, N Auger, L Lacroix, JC Soria
Annals of Oncology 26 (10), 2073-2078, 2015
|Prevalence and causes of burnout amongst oncology residents: a comprehensive nationwide cross-sectional study|
P Blanchard, D Truchot, L Albiges-Sauvin, S Dewas, Y Pointreau, ...
European journal of cancer 46 (15), 2708-2715, 2010
|Enfortumab vedotin in previously treated advanced urothelial carcinoma|
T Powles, JE Rosenberg, GP Sonpavde, Y Loriot, I Durán, JL Lee, ...
New England Journal of Medicine 384 (12), 1125-1135, 2021
|Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with …|
Y Loriot, K Miller, CN Sternberg, K Fizazi, JS De Bono, S Chowdhury, ...
The Lancet Oncology 16 (5), 509-521, 2015
|Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies|
S Antoun, E Lanoy, R Iacovelli, L Albiges‐Sauvin, Y Loriot, ...
Cancer 119 (18), 3377-3384, 2013
|Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma …|
T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ...
The Lancet Oncology 21 (12), 1574-1588, 2020